Share information
265.70 €
-1.81 %
15/04/2026 17:36
-1.81 %
Open
High
Low
Volume
270.30 €
273.40 €
265.70 €
296,521
Latest News
15-Apr-2026
UCB presents new data demonstrating quality-of-life impacts for epilepsy patients and caregivers at AAN 2026 meeting
10-Apr-2026
Acquisition of own shares
03-Apr-2026
Acquisition of own shares
31-Mar-2026
European Commission approves KYGEVVI[®]▼ (doxecitine and doxribtimine) as first and only treatment for Thymidine Kinase 2 Deficiency (TK2d)